History of gene therapy

Gene

Volumn 525, Issue 2, 2013, Pages 162-169

  Wirth, Thomas ^a   Parker, Nigel ^b   Ylä Herttuala, Seppo ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b FKD Therapies Oy   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Clinical trials; Ethics; Gene therapy; History; Safety; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ALIPOGENE TIPARVOVEC; AMINOPTERIN; ANTINEOPLASTIC AGENT; DEAMINASE; DIHYDROFOLATE REDUCTASE; DNA; GENDICINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERLEUKIN 2; LIPOPROTEIN LIPASE; MONOCLONAL ANTIBODY; NEOMYCIN; ONCORINE; RECOMBINANT DNA; SITIMAGENE CERADENOVEC; THYMIDINE KINASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM TRANSFORMATION; BETA THALASSEMIA; BRAIN CANCER; CELL TRANSFORMATION; CHEMOTHERAPY; CHRONIC GRANULOMATOUS DISEASE; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOPHILIA B; HISTORY; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IN VIVO GENE TRANSFER; LONG TERM SURVIVAL; LYMPHOCYTE; MEDICAL ETHICS; MELANOMA; NASOPHARYNX CANCER; NECROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SALMONELLA; STREPTOCOCCUS PNEUMONIAE; VIRAL GENE DELIVERY SYSTEM; WISKOTT ALDRICH SYNDROME;

ADA-SCID; ADENOSINE DEAMINASE DEFICIENCY; ADENOVIRAL GENE; CDNA; CHINA'S STATE FOOD AND DRUG ADMINISTRATION; CHMP; CLINICAL TRIALS; COMMITTEE ON HUMAN MEDICINAL PRODUCTS; COMPLEMENTARY DNA; DEOXYRIBONUCLEIC ACID; DHFR; DIHYDROFOLATE REDUCTASE; DNA; E1; E1B 55K; EMA; ETHICS; EUROPEAN MEDICINES AGENCY; FDA; GANCICLOVIR; GCV; GENE THERAPY; GMP; GOOD MANUFACTURING PRACTISE; HAT MEDIUM; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HGPRT; HISTORY; HSV-TK; HYPOXANTHINE AND THYMIDINE CONTAINING MEDIUM; HYPOXANTHINE-GUANINE PHOSPHORIBOSYL TRANSFERASE; NEOMYCIN RESISTANCE GENE; NEOR; ORNITHINE TRANSCARBAMYLASE; OTC; P53; PEG-ADA; POLYETHYLENE GLYCOL ADENINE DEAMINASE; PROTEIN 53, A TUMOUR SUPPRESSOR; RAC; RECOMBINANT DNA ADVISORY COMMITTEE; RIBONUCLEIC ACID; RNA; ROUS SARCOMA VIRUS; RSV; SAFETY; SFDA; TALEN; TIL; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE; TUMOUR-INFILTRATING LYMPHOCYTE; UCLA; UNIVERSITY OF CALIFORNIA, LOS ANGELES; US FOOD AND DRUG ADMINISTRATION; VIRAL VECTORS; ZFN; ZINC FINGER NUCLEASES;

CHINA; EUROPEAN UNION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; TRANSDUCTION, GENETIC;

EID: 84879879026     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.137     Document Type: Article

References (53)

1. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., Scaramuzza S., Andolfi G., Mirolo M., Brigida I., Tabucchi A., Carlucci F., Eibl M., Aker M., Slavin S., Al-Mousa H., Al Ghonaium A., Ferster A., Duppenthaler A., Notarangelo L., Wintergerst U., Buckley R.H., Bregni M., Marktel S., Valsecchi M.G., Rossi P., Ciceri F., Miniero R., Bordignon C., Roncarolo M.G. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360:447-458.
2. Alloway J.L. The Transformation in Vitro of R Pneumococci into S Forms of Different Specific Types by the use of Filtered Pneumococcus Extracts. J. Exp. Med. 1932, 55:91-99.
3. Alloway J.L. Further Observations on the use of Pneumococcus Extracts in Effecting Transformation of Type in Vitro. J. Exp. Med. 1933, 57:265-278.
4. Avery O.T., Macleod C.M., McCarty M. Studies on the Chemical Nature of the Substance Inducing Transformation of Pneumococcal Types: Induction of Transformation by a Desoxyribonucleic Acid Fraction Isolated from Pneumococcus Type Iii. J. Exp. Med. 1944, 79:137-158.
5. Beutler E. The Cline affair. Mol. Ther. 2001, 4:396-397.
6. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
7. Blaese R.M., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C.A., Ramsey W.J., Muul L., Morgan R.A., Anderson W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270:475-480.
8. Bordignon C., Notarangelo L.D., Nobili N., Ferrari G., Casorati G., Panina P., Mazzolari E., Maggioni D., Rossi C., Servida P., Ugazio A.G., Mavilio F. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995, 270:470-475.
9. Boztug K., Schmidt M., Schwarzer A., Banerjee P.P., Diez I.A., Dewey R.A., Bohm M., Nowrouzi A., Ball C.R., Glimm H., Naundorf S., Kuhlcke K., Blasczyk R., Kondratenko I., Marodi L., Orange J.S., von Kalle C., Klein C. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 2010, 363:1918-1927.
10. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
11. Cavazzana-Calvo M., Payen E., Negre O., Wang G., Hehir K., Fusil F., Down J., Denaro M., Brady T., Westerman K., Cavallesco R., Gillet-Legrand B., Caccavelli L., Sgarra R., Maouche-Chretien L., Bernaudin F., Girot R., Dorazio R., Mulder G.J., Polack A., Bank A., Soulier J., Larghero J., Kabbara N., Dalle B., Gourmel B., Socie G., Chretien S., Cartier N., Aubourg P., Fischer A., Cornetta K., Galacteros F., Beuzard Y., Gluckman E., Bushman F., Hacein-Bey-Abina S., Leboulch P. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467:318-322.
12. Dawson M.H., Sia R.H.P. In Vitro Transformation of Pneumococcal Types: I. a Technique for Inducing Transformation of Pneumococcal Types in Vitro. J. Exp. Med. 1931, 54:681-699.
13. Donsante A., Vogler C., Muzyczka N., Crawford J.M., Barker J., Flotte T., Campbell-Thompson M., Daly T., Sands M.S. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001, 8:1343-1346.
14. Fehse B., Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther. 2008, 15:143-153.
15. Friedmann T. Medical ethics. Principles for human gene therapy studies. Science 2000, 287:2163-2165.
16. Friedmann T., Roblin R. Gene therapy for human genetic disease?. Science 1972, 175:949-955.
17. Griffith F. The Significance of Pneumococcal Types. J. Hyg. (Lond) 1928, 27:113-159.
18. Guo J., Xin H. Chinese gene therapy. Splicing out the West?. Science 2006, 314:1232-1235.
19. Hacein-Bey-Abina S., Hauer J., Lim A., Picard C., Wang G.P., Berry C.C., Martinache C., Rieux-Laucat F., Latour S., Belohradsky B.H., Leiva L., Sorensen R., Debre M., Casanova J.L., Blanche S., Durandy A., Bushman F.D., Fischer A., Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2010, 363:355-364.
20. Hedman M., Muona K., Hedman A., Kivela A., Syvanne M., Eranen J., Rantala A., Stjernvall J., Nieminen M.S., Hartikainen J., Yla-Herttuala S. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 2009, 16:629-634.
21. Immonen A., Vapalahti M., Tyynela K., Hurskainen H., Sandmair A., Vanninen R., Langford G., Murray N., Yla-Herttuala S. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 2004, 10:967-972.
22. 2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators.
23. Li H., Malani N., Hamilton S.R., Schlachterman A., Bussadori G., Edmonson S.E., Shah R., Arruda V.R., Mingozzi F., Wright J.F., Bushman F.D., High K.A. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2011, 117:3311-3319.
24. Maguire A.M., High K.A., Auricchio A., Wright J.F., Pierce E.A., Testa F., Mingozzi F., Bennicelli J.L., Ying G.S., Rossi S., Fulton A., Marshall K.A., Banfi S., Chung D.C., Morgan J.I., Hauck B., Zelenaia O., Zhu X., Raffini L., Coppieters F., De Baere E., Shindler K.S., Volpe N.J., Surace E.M., Acerra C., Lyubarsky A., Redmond T.M., Stone E., Sun J., McDonnell J.W., Leroy B.P., Simonelli F., Bennett J. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374:1597-1605.
25. Marcaida M.J., Munoz I.G., Blanco F.J., Prieto J., Montoya G. Homing endonucleases: from basics to therapeutic applications. Cell Mol. Life Sci. 2010, 67:727-748.
26. Mercola K.E., Stang H.D., Browne J., Salser W., Cline M.J. Insertion of a new gene of viral origin into bone marrow cells of mice. Science 1980, 208:1033-1035.
27. Mercola K.E., Bar-Eli M., Stang H.D., Slamon D.J., Cline M.J. Insertion of new genetic information into bone marrow cells of mice: comparison of two selectable genes. Ann. N. Y. Acad. Sci. 1982, 397:272-280.
28. Moolten F.L., Wells J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 1990, 82:297-300.
29. Muona K., Makinen K., Hedman M., Manninen H., Yla-Herttuala S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther. 2012, 19(4):392-395.
30. Mussolino C., Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr. Opin. Biotechnol. 2012, 23:644-650.
31. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 2005, 16:1016-1027.
32. Puumalainen A.M., Vapalahti M., Agrawal R.S., Kossila M., Laukkanen J., Lehtolainen P., Viita H., Paljarvi L., Vanninen R., Yla-Herttuala S. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 1998, 9:1769-1774.
33. Rogers S., Pfuderer P. Use of viruses as carriers of added genetic information. Nature 1968, 219:749-751.
34. Rogers S., Lowenthal A., Terheggen H.G., Columbo J.P. Induction of arginase activity with the Shope papilloma virus in tissue culture cells from an argininemic patient. J. Exp. Med. 1973, 137:1091-1096.
35. Rosenberg S.A. Gene therapy for cancer. JAMA 1992, 268:2416-2419.
36. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988, 319:1676-1680.
37. Rosenberg S.A., Aebersold P., Cornetta K., Kasid A., Morgan R.A., Moen R., Karson E.M., Lotze M.T., Yang J.C., Topalian S.L. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323:570-578.
38. Rosenberg S.A., Anderson W.F., Blaese M., Hwu P., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Ettinghausen S.E. The development of gene therapy for the treatment of cancer. Ann. Surg. 1993, 218:455-463. (discussion 463-4).
39. Sambrook J., Westphal H., Srinivasan P.R., Dulbecco R. The integrated state of viral DNA in SV40-transformed cells. Proc. Natl. Acad. Sci. U. S. A. 1968, 60:1288-1295.
40. Sandmair A.M., Loimas S., Puranen P., Immonen A., Kossila M., Puranen M., Hurskainen H., Tyynela K., Turunen M., Vanninen R., Lehtolainen P., Paljarvi L., Johansson R., Vapalahti M., Yla-Herttuala S. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 2000, 11:2197-2205.
41. Stolberg, S.G., 1999. The biotech death of Jesse Gelsinger. N.Y.Times Mag. 136-140, 149-150.
42. Szybalska E.H., Szybalski W. Genetics of human cess line. IV. DNA-mediated heritable transformation of a biochemical trait. Proc. Natl. Acad. Sci. U. S. A. 1962, 48:2026-2034.
43. Tatum E.L. Molecular biology, nucleic acids, and the future of medicine. Perspect. Biol. Med. 1966, 10:19-32.
44. Tatum E.L., Lederberg J. Gene Recombination in the Bacterium Escherichia coli. J. Bacteriol. 1947, 53:673-684.
45. Temin H.M. Mixed infection with two types of Rous sarcoma virus. Virology 1961, 13:158-163.
46. Terheggen H.G., Lowenthal A., Lavinha F., Colombo J.P., Rogers S. Unsuccessful trial of gene replacement in arginase deficiency. Z. Kinderheilkd. 1975, 119:1-3.
47. Urnov F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 2010, 11:636-646.
48. Wilson J.M. Gendicine: the first commercial gene therapy product. Hum. Gene Ther. 2005, 16:1014-1015.
49. Wirth T., Hedman M., Makinen K., Manninen H., Immonen A., Vapalahti M., Yla-Herttuala S. Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr. Drug Saf. 2006, 1:253-257.
50. Wirth T., Samaranayake H., Pikkarainen J., Maatta A.M., Yla-Herttuala S. Clinical trials for glioblastoma multiforme using adenoviral vectors. Curr. Opin. Mol. Ther. 2009, 11:485-492.
51. Xin H. Chinese gene therapy. Gendicine's efficacy: hard to translate. Science 2006, 314:1233.
52. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther. 2012, 20:1831-1832.
53. Zinder N.D., Lederberg J. Genetic exchange in Salmonella. J. Bacteriol. 1952, 64:679-699.